

April 2012

1. *Please confirm or deny whether your trust has submitted applications for cancer drugs using the Cancer Drugs Fund between April 2011 and February 2012 inclusive.*

Southend University Hospital NHS Foundation Trust has submitted applications for cancer drugs using the Cancer Drugs Fund between April 2011 and February 2012

2. *Please supply the number of applications that your trust has submitted for cancer drugs using the Cancer Drugs Fund between April 2011 and February 2012 inclusive, broken down by cancer treatment and indication.*

Treatment	Indication	Number of applications
Bevacizumab IRMDG	Metastatic Colorectal Cancer (MCRC)	21
Bevacizumab OXMDG	MCRC	10
Bevacizumab OXCAP	MCRC	2
Bevacizumab IRINOCAP	MCRC	1
Cetuximab IRINOCAP	MCRC	4
Cetuximab Single Agent	MCRC	2
Cetuximab OXMDG	MCRC	5
Cetuximab IRMDG	MCRC	14
Cetuximab CISP 5FU	Head And Neck	4
Erlotinib	2 <sup>nd</sup> Line NSCLC	41
Erlotinib	1 <sup>st</sup> Line Maintenance Treatment NSCLC	2
Sorafenib	Hepatocellular Carcinoma	1
Lapatinib & Capecitabine	Breast	7
Lapatinib & A.I.	Breast	3
Bevacizumab & Paclitaxel	Breast	1
Eribulin	Breast	1
Cabazitazell	Prostate	3
Abiraterone	Prostate	2
Everolimus	Renal Cell Cancer	6
Rituximab & Bendamustine	NHL	2
Ipilimumab	Melanoma	1

**ABBREVIATIONS:**

IRMDG= Irinotecan and Modified de Gramont

OXMDG= Oxaliplatin

OXCAP= Oxaliplatin and Capecitabine

IRINOCAP= Irinotecan and Capecitabine

CISP= Cisplatin

5FU= 5 Fluorouracil

- 3. Please confirm or deny whether your trust has submitted applications for cancer drugs to be used outside of their licensed indication (off-label) using the Cancer Drugs Fund between April 2011 and February 2012 inclusive.*

Southend University Hospital NHS Foundation Trust has not applied for drugs to be used outside of their licensed information using the Cancer Drugs Fund during the period specified.